147984-94-9

Upstream product

• 108-30-5 succinic acid anhydride 
• 1738-76-7 glycine benzyl ester p-toluenesulfonic acid salt 
• 2462-31-9 benzyl 2-aminoacetate hydrochloride 

Downstream Products

• 147984-96-1 succinyl bis 
• 804483-30-5 [3-(benzyloxycarbonylmethyl-carbamoyl)-propionylamino]-acetic acid tert-butyl ester 
• 92029-72-6 C₁₃H₁₃NO₄ 
• 147984-99-4 succinyl bis 
• 147984-98-3 succinyl bis  
• 807344-22-5 C₇₂H₇₇N₁₁O₁₂ 
• 804483-34-9 C₄₁H₄₃N₅O₈ 
• 714978-20-8 carbobenzyloxy-glycyl-succinyl-glycine 

Relevant academic research and scientific papers

MYCOBACTERIAL INHIBITORS

The invention provides the use of certain succinimide compounds in the treatment of mycobacterial diseases.

A bivalent ligand (KDN-21) reveals spinal δ and κ opioid receptors are organized as heterodimers that give rise to δ1 and δ2 phenotypes. Selective targeting of δ-κ heterodimers

In view of recent pharmacological studies suggesting the existence of δ-κ opioid receptor heterodimers/oligomers in the spinal cord, we have synthesized and evaluated (intrathecally in mice) a series of bivalent ligands (KDN series) containing κ and δ antagonist pharmacophores. Pharmacological and binding data have provided evidence for the bridging of spinal δ-κ receptor heterodimers by KDN-21 and for their identification as δ1 and κ2. The selectivity profile of KDN-21 and the apparent absence of coupled δ 1-κ2 phenotypes in the brain suggest a new approach for targeting receptors.